[go: up one dir, main page]

ATE504557T1 - Aspirin-ausgelöste lipidmediatoren - Google Patents

Aspirin-ausgelöste lipidmediatoren

Info

Publication number
ATE504557T1
ATE504557T1 AT06022386T AT06022386T ATE504557T1 AT E504557 T1 ATE504557 T1 AT E504557T1 AT 06022386 T AT06022386 T AT 06022386T AT 06022386 T AT06022386 T AT 06022386T AT E504557 T1 ATE504557 T1 AT E504557T1
Authority
AT
Austria
Prior art keywords
aspirin
lipid mediators
released lipid
released
mediators
Prior art date
Application number
AT06022386T
Other languages
English (en)
Inventor
Clary B Clish
Charles N Serhan
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE504557T1 publication Critical patent/ATE504557T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06022386T 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren ATE504557T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18307800P 2000-02-16 2000-02-16
US23881400P 2000-10-06 2000-10-06

Publications (1)

Publication Number Publication Date
ATE504557T1 true ATE504557T1 (de) 2011-04-15

Family

ID=26878731

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06022386T ATE504557T1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren
AT01910912T ATE344226T1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01910912T ATE344226T1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren

Country Status (11)

Country Link
US (5) US6670396B2 (de)
EP (2) EP1296923B3 (de)
JP (5) JP4932116B2 (de)
CN (4) CN102010324B (de)
AT (2) ATE504557T1 (de)
AU (4) AU3846801A (de)
CA (1) CA2400462C (de)
DE (2) DE60144401D1 (de)
IL (1) IL151299A0 (de)
MX (1) MXPA02007915A (de)
WO (1) WO2001060778A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144401D1 (de) * 2000-02-16 2011-05-19 Brigham & Womens Hospital Aspirin-ausgelöste Lipidmediatoren
WO2001070664A2 (en) * 2000-03-20 2001-09-27 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
BR0207663A (pt) * 2001-02-27 2005-10-25 Univ Michigan Uso de inibidores de egfr naturais para prevenir os efeitos colaterais devido à terapia com retinóides, sabões e outros estìmulos que ativam o receptor do fator de crescimento epidérmico
AU2002252175A1 (en) * 2001-03-02 2002-09-19 The Brigham And Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
DE60236467D1 (de) 2001-03-02 2010-07-01 Brigham And Women S Hospital B Lipoxinanaloge als neuartige Restenose-Hemmer
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
WO2002102364A1 (fr) * 2001-06-18 2002-12-27 Yamada, Sachiko Preparations medicamenteuses agonistes ppar$g(g)
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
WO2003053423A2 (en) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US20030195248A1 (en) * 2001-12-18 2003-10-16 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with lipoxin compounds
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
EP1528909A4 (de) * 2002-04-01 2006-05-24 Univ Southern California Trihydroxy-polyungesättigte eicosanoide
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
ATE382597T1 (de) * 2002-06-17 2008-01-15 Resolvyx Pharmaceuticals Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren
DK2216318T3 (en) * 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
EP1551382A4 (de) * 2002-09-27 2007-01-24 Martek Biosciences Corp Prophylaktische behandlung mit docosahexaensäure für patienten mit subklinischer entzündung
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
MXPA05013251A (es) * 2003-07-07 2006-03-09 Hills Pet Nutrition Inc Composiciones para estado de oxigeno mejorado en animales de compania.
WO2005105025A1 (en) * 2004-04-14 2005-11-10 Boston University Methods and compositions for preventing or treating periodontal diseases
US20060002985A1 (en) * 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
DE202005022112U1 (de) * 2004-10-08 2014-04-24 Forward Pharma A/S Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
KR20070090928A (ko) * 2004-11-19 2007-09-06 마텍 바이오싸이언스스 코포레이션 장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US8636986B2 (en) 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
WO2007090162A2 (en) * 2006-01-31 2007-08-09 Martek Biosciences Corporation OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
EP2049099A1 (de) * 2006-07-19 2009-04-22 Resolvyx Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von mukositis
WO2008057283A2 (en) * 2006-10-26 2008-05-15 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
US20080161275A1 (en) * 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
AU2008274876A1 (en) * 2007-02-05 2009-01-15 Children, Youth And Women's Health Service Modulators of antigen-dependent T cell proliferation
JP2010519311A (ja) * 2007-02-20 2010-06-03 マーテック バイオサイエンシーズ コーポレーション 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
JP2010539167A (ja) * 2007-09-14 2010-12-16 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 免疫機能を調節する組成物および方法
WO2009051670A2 (en) * 2007-10-12 2009-04-23 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for the treatment of ophthalmic conditions
WO2009086281A1 (en) * 2007-12-21 2009-07-09 Martek Biosciences Corporation Method for preparation of oxylipins
CA2729053A1 (en) 2008-05-01 2009-11-05 Bruce A. Freeman Vinyl substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2324827A4 (de) * 2008-08-22 2012-04-25 Mochida Pharm Co Ltd Therapeutischer wirkstoff für anca-assoziierte vaskulitiden
JP6046345B2 (ja) 2008-09-16 2016-12-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． １４−ヒドロキシ−ドコサヘキサエン酸化合物
US20110190242A1 (en) * 2008-09-23 2011-08-04 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
JP5523439B2 (ja) 2009-02-20 2014-06-18 国立大学法人 東京大学 新規抗炎症性化合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US9066902B2 (en) 2009-07-31 2015-06-30 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
CA2781276A1 (en) 2009-10-02 2011-04-07 Complexa, Inc. Heteroatom containing substituted fatty acids
US20130137767A1 (en) * 2010-02-02 2013-05-30 Dsm Ip Assets B.V. Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid
US9238634B2 (en) 2010-08-19 2016-01-19 The University Of Tokyo Anti-inflammatory metabolite derived from omega-3-type fatty acid
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
FR2979824A1 (fr) * 2011-09-13 2013-03-15 Vetinnov Composition a usage humain ou veterinaire.
JP5969186B2 (ja) * 2011-09-15 2016-08-17 出光興産株式会社 Ｇｐｒ１１９アゴニスト並びにそれを含むインスリン分泌促進剤、血糖降下剤および糖尿病の治療または予防剤
WO2013044176A2 (en) * 2011-09-23 2013-03-28 University Of Southern California Methods and compositions for the treatment of ischemic stroke
CA2864797C (en) 2012-02-15 2022-03-22 Anida Pharma Inc. Methods of treating amyotrophic lateral sclerosis
NZ702325A (en) 2012-05-10 2016-09-30 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
EP4218729A1 (de) 2012-08-24 2023-08-02 Sun Pharmaceutical Industries Limited Topische formulierungen und verwendungen davon
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CA2902232C (en) 2013-02-22 2020-12-29 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
USRE48077E1 (en) 2013-02-28 2020-07-07 Anida Pharma Inc. Methods of treating ototoxicity
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
MX2016008953A (es) * 2014-01-10 2017-02-02 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
CN107072959A (zh) 2014-06-04 2017-08-18 尊严科学有限公司 包含二高γ亚麻酸(DGLA)的医药组合物以及其用途
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN107438366B (zh) 2015-03-18 2022-03-15 福塞斯儿童牙科医院 使用脂氧素、消退素及其类似物稳定动脉粥状硬化斑块的方法
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
HRP20240082T1 (hr) 2015-07-07 2024-03-29 H. Lundbeck A/S Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
CN108025181A (zh) * 2015-07-21 2018-05-11 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
US10537541B2 (en) 2015-10-02 2020-01-21 Complexa Inc. Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
EP4364810A3 (de) 2015-11-10 2024-07-24 Sun Pharmaceutical Industries Limited Topische formulierungen und verwendungen davon
MX394051B (es) 2015-12-18 2025-03-24 Afimmune Ltd Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo
US11903998B2 (en) 2016-05-27 2024-02-20 Forsyth Dental Infirmary For Children Compositions and methods of treating cancer using lipid agonists and receptors thereof
CN109562186B (zh) 2016-06-03 2022-09-13 西蒂斯制药有限责任公司 与专门促消退介质的盐有关的组合物和方法
CN105924338B (zh) * 2016-06-17 2019-03-01 中科瑞奥能源科技股份有限公司 丁醇尾气回收工艺与系统
US11111222B2 (en) 2016-06-23 2021-09-07 The Regents Of The University Of Michigan Hydroxyeicosatrienoic acid compounds and their use as therapeutic agents
WO2018161175A1 (en) 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2019182191A1 (ko) * 2018-03-21 2019-09-26 경북대학교 산학협력단 C0x2 아세틸화제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
DK3801526T3 (da) 2018-05-25 2024-03-25 Cardurion Pharmaceuticals Inc Monohydrate og krystallinske former af 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imidazo[1,5-a]pyrazin-8-on
BR112021003686A2 (pt) 2018-08-31 2021-05-18 Imara Inc. inibidores de pde9 para tratar doença falciforme
EP3863622B1 (de) 2018-10-09 2024-07-24 University Of Rochester Behandlung von vulvovaginalen störungen
EP3886613A1 (de) * 2018-11-30 2021-10-06 Evonik Operations GmbH Zubereitung mit einem probiotischen stamm der gattung bacillus megaterium und einer mehrfach ungesättigten fettsäurekomponente
EP3946308A4 (de) * 2019-04-04 2022-12-14 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Sehr langkettige mehrfach ungesättigte fettsäuren, elovanoidhydroxylierte derivate und verfahren zur verwendung
US20230125690A1 (en) * 2019-09-20 2023-04-27 Jae-sung Bae Antibody for detecting acetylation of cox2 protein, and uses thereof
KR20220163468A (ko) * 2020-04-03 2022-12-09 애피뮨 리미티드 혈액학적 장애 및/또는 관련 질환을 치료 또는 예방하기 위한 15-hepe를 포함하는 조성물
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
KR20240150603A (ko) 2022-03-03 2024-10-15 테티스 파마수티컬스 엘엘씨 특수화된 해소촉진 매개체의 시클로덱스트린 복합체
WO2025023183A1 (ja) * 2023-07-21 2025-01-30 国立大学法人大阪大学 炎症性腸疾患を抑制する脂肪酸代謝産物

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466701A (en) 1892-01-05 Hiram ezkiel payne
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
GB2033745B (en) 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
US4567290A (en) 1981-11-27 1986-01-28 Research Corporation Leukotriene analogues
US4442099A (en) 1981-11-27 1984-04-10 Research Corporation Leukotriene analogues
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4759880A (en) 1984-09-27 1988-07-26 Research Corporation Alkanoarachidonic acids
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4710521A (en) 1986-07-25 1987-12-01 The Celotex Corporation Catalyst mixtures for polyisocyanurate foam
US4810424A (en) * 1987-10-09 1989-03-07 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados
US5136501A (en) 1989-05-26 1992-08-04 Reuters Limited Anonymous matching system
EP0573423A4 (en) * 1990-05-07 1994-06-01 Barry I Bockow Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof
JPH0425036A (ja) 1990-05-16 1992-01-28 Mitsubishi Electric Corp マイクロ波半導体装置
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5087790A (en) 1991-06-12 1992-02-11 University Of Southern California Method for olefination of carbonyl compounds using titanocene derivatives
WO1993000084A1 (en) 1991-06-24 1993-01-07 Adelaide Children's Hospital Methods and compositions for treating malaria and other diseases
US5177046A (en) 1991-09-20 1993-01-05 Air Products And Chemicals, Inc. Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US5409955A (en) * 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US5411988A (en) 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
JP2536436B2 (ja) 1993-11-19 1996-09-18 日本電気株式会社 モ―ルド型半導体装置
US6030917A (en) 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
US5752238A (en) 1994-11-03 1998-05-12 Intel Corporation Consumer-driven electronic information pricing mechanism
US5594732A (en) 1995-03-03 1997-01-14 Intecom, Incorporated Bridging and signalling subsystems and methods for private and hybrid communications systems including multimedia systems
US5801280A (en) 1995-04-07 1998-09-01 Sumitomo Chemical Company, Limited Processes for preparing optically active alcohols and optically active amines
US5845265A (en) 1995-04-26 1998-12-01 Mercexchange, L.L.C. Consignment nodes
US5756789A (en) 1995-06-08 1998-05-26 Texaco, Inc. Synthesis of metal--containing aluminophosphates with layered structure
CA2182851A1 (en) 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US5709855A (en) * 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5870717A (en) 1995-11-13 1999-02-09 International Business Machines Corporation System for ordering items over computer network using an electronic catalog
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
PT1288206E (pt) 1996-04-12 2008-11-14 Searle Llc Derivados de benzenossulfonamida substituídos como pró-fármacos de inibidores de cox-2
US5878400A (en) 1996-06-17 1999-03-02 Trilogy Development Group, Inc. Method and apparatus for pricing products in multi-level product and organizational groups
US5842040A (en) 1996-06-18 1998-11-24 Storage Technology Corporation Policy caching method and apparatus for use in a communication device based on contents of one data unit in a subset of related data units
AU3718397A (en) 1996-06-28 1998-01-21 University Of Southern California Method for the synthesis of amines and amino acids with organoboron derivatives
US5890138A (en) 1996-08-26 1999-03-30 Bid.Com International Inc. Computer auction system
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US5896379A (en) 1996-08-26 1999-04-20 Motorola, Inc. Network node for packet switching with selective data processing and method therefor
US5912006A (en) 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
US5946467A (en) 1996-09-20 1999-08-31 Novell, Inc. Application-level, persistent packeting apparatus and method
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6201022B1 (en) * 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6428990B1 (en) 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
US5878423A (en) 1997-04-21 1999-03-02 Bellsouth Corporation Dynamically processing an index to create an ordered set of questions
US6030715A (en) 1997-10-09 2000-02-29 The University Of Southern California Azlactone-related dopants in the emissive layer of an OLED
US6259699B1 (en) 1997-12-30 2001-07-10 Nexabit Networks, Llc System architecture for and method of processing packets and/or cells in a common switch
JP2002513750A (ja) 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
US6377937B1 (en) 1998-05-28 2002-04-23 Paskowitz Associates Method and system for more effective communication of characteristics data for products and services
US6069109A (en) 1998-07-01 2000-05-30 Union Carbide Chemicals & Plastics Technology Corporation Process for the production of half-sandwich transition metal based catalyst precursors
US6336138B1 (en) 1998-08-25 2002-01-01 Hewlett-Packard Company Template-driven approach for generating models on network services
WO2000024510A1 (en) 1998-10-23 2000-05-04 University Of Southern California Combinatorial approach to chiral reagents or catalysts having amine or amino alcohol ligands
US6336105B1 (en) 1998-11-16 2002-01-01 Trade Access Inc. System and method for representing data and providing electronic non-repudiation in a negotiations system
DE19855426A1 (de) 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
US6272474B1 (en) 1999-02-08 2001-08-07 Crisostomo B. Garcia Method for monitoring and trading stocks via the internet displaying bid/ask trade bars
US6397212B1 (en) 1999-03-04 2002-05-28 Peter Biffar Self-learning and self-personalizing knowledge search engine that delivers holistic results
CA2747376A1 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
ES2246230T3 (es) 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
CA2367160A1 (en) 1999-03-18 2000-09-21 Charles N. Serhan Leukotriene b4 receptor transgenic mammals
ES2344138T3 (es) 1999-03-18 2010-08-19 The Brigham And Women's Hospital, Inc. Analogos de 16-fenoxi-lipoxina para utilizacion medica.
US6427132B1 (en) 1999-08-31 2002-07-30 Accenture Llp System, method and article of manufacture for demonstrating E-commerce capabilities via a simulation on a network
US6415270B1 (en) 1999-09-03 2002-07-02 Omnihub, Inc. Multiple auction coordination method and system
DE60144401D1 (de) 2000-02-16 2011-05-19 Brigham & Womens Hospital Aspirin-ausgelöste Lipidmediatoren
WO2001070664A2 (en) 2000-03-20 2001-09-27 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
US6473314B1 (en) 2000-08-03 2002-10-29 Powerwave Technologies, Inc. RF power amplifier assembly employing multi-layer RF blocking filter
US20020074162A1 (en) 2000-12-15 2002-06-20 Bor-Ray Su Substrate layout method and structure for reducing cross talk of adjacent signals
AU2002252175A1 (en) 2001-03-02 2002-09-19 The Brigham And Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
US20040044028A1 (en) 2001-03-30 2004-03-04 Obukowicz Mark G. Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer
CA2465117C (en) 2001-11-06 2012-01-03 Brigham And Women's Hospital, Inc. Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US20030195248A1 (en) 2001-12-18 2003-10-16 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with lipoxin compounds
WO2003053423A2 (en) 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
EP1528909A4 (de) * 2002-04-01 2006-05-24 Univ Southern California Trihydroxy-polyungesättigte eicosanoide
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
ATE382597T1 (de) 2002-06-17 2008-01-15 Resolvyx Pharmaceuticals Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DK2216318T3 (en) 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2004263164A1 (en) 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer's disease and retinal degeneration
WO2005105025A1 (en) 2004-04-14 2005-11-10 Boston University Methods and compositions for preventing or treating periodontal diseases
US20060293288A1 (en) 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
EP2049099A1 (de) 2006-07-19 2009-04-22 Resolvyx Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von mukositis

Also Published As

Publication number Publication date
US7709669B2 (en) 2010-05-04
CN102010324B (zh) 2014-04-02
AU2006225252A1 (en) 2006-11-02
CN1680259A (zh) 2005-10-12
US20070049639A1 (en) 2007-03-01
JP2015007046A (ja) 2015-01-15
MXPA02007915A (es) 2005-06-20
EP1762557B1 (de) 2011-04-06
ATE344226T1 (de) 2006-11-15
DE60124256T2 (de) 2007-05-31
CA2400462A1 (en) 2001-08-23
US6670396B2 (en) 2003-12-30
CN1951899B (zh) 2012-02-01
JP4932116B2 (ja) 2012-05-16
JP2019108348A (ja) 2019-07-04
CN100357244C (zh) 2007-12-26
EP1762557A2 (de) 2007-03-14
US20090149538A1 (en) 2009-06-11
JP2003525880A (ja) 2003-09-02
AU2006225252B2 (en) 2009-02-26
JP2010248213A (ja) 2010-11-04
US7053230B2 (en) 2006-05-30
AU2006225252A2 (en) 2006-11-02
AU3846801A (en) 2001-08-27
WO2001060778A2 (en) 2001-08-23
CN1469858A (zh) 2004-01-21
US20100216882A1 (en) 2010-08-26
US20040059144A1 (en) 2004-03-25
DE60144401D1 (de) 2011-05-19
CN1951899A (zh) 2007-04-25
WO2001060778A9 (en) 2002-10-24
US7737178B2 (en) 2010-06-15
CA2400462C (en) 2011-09-27
IL151299A0 (en) 2003-04-10
EP1296923B1 (de) 2006-11-02
JP2016006057A (ja) 2016-01-14
JP5973503B2 (ja) 2016-08-23
WO2001060778A3 (en) 2003-01-16
US20020055538A1 (en) 2002-05-09
EP1296923A2 (de) 2003-04-02
AU2001238468B2 (en) 2006-07-06
CN1202068C (zh) 2005-05-18
DE60124256D1 (de) 2006-12-14
DE60124256T3 (de) 2012-09-20
EP1762557A3 (de) 2007-11-07
AU2009202071A1 (en) 2009-06-18
EP1296923B3 (de) 2012-04-11
HK1105948A1 (en) 2008-02-29
US8349896B2 (en) 2013-01-08
CN102010324A (zh) 2011-04-13
AU2009202071B2 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
DE60124256D1 (de) Aspirin-ausgelöste lipidmediatoren
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
ITMI20001317A0 (it) Procedimento per la purificazione di diacereina.
ES1048243Y (es) Maquina para la prepoda de arboles.
NL1014850A1 (nl) Grafkist.
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
ITSV20010001U4 (it) Vedi invenzione n. 16 del 1998
ES1049731Y (es) Dispositivo para la administracion de farmacos.
IT1318631B1 (it) Procedimento per la produzione di alfa-olefine.
BR8101523Y1 (pt) disposição construtiva aplicada à cadeira.
IT1320253B1 (it) Composizione farmaceutica per il trattamento della malaria.
BR8001273Y1 (pt) suspensório médico.
TH103000094A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH101001395A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000080A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000076A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000361A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000093A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000058A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000088A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000056A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000085A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000048A (th) สิทธิบัตรยังไม่ประกาศโฆษณา

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties